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Epidemiology
Yellow fever (YF) virus is transmitted to humans primarily through the bite of an
infected Aedes or Haemagogus sp. mosquito. The virus is present in sub-Saharan Africa
and tropical South America, where it is endemic and intermittently epidemic [1].
The World Health Organization (WHO) estimates that 200,000 cases of YF, including
30,000 deaths, occur annually worldwide.
YF virus has three transmission cycles: sylvatic (jungle), intermediate (savannah),
and urban [2]. Most YF disease in humans is due to sylvatic or intermediate trans-
mission cycles. However, urban YF occurs periodically in Africa and sporadically in
the Americas.
In Africa, most outbreaks have been reported from West Africa, with fewer out-
breaks being reported from Central and East Africa [2]. YF virus transmission in rural
West Africa is seasonal, with an elevated risk during the end of the rainy season and
the beginning of the dry season (usually July–October) [3]. However, YF virus may
be episodically transmitted by Ae. aegypti even during the dry season in both rural
and densely settled urban areas [2].
In South America, transmission of YF virus occurs predominantly in
sparsely-populated forested areas. Consequently, YF occurs most frequently in
unimmunized young men who are exposed to mosquitoes through work in forested
areas [2]. The risk for infection in South America is highest during the rainy season
(January–May) [3].
Clinical manifestation, diagnosis, and treatment
Most people infected with YF virus are asymptomatic. For symptomatic illness, the
incubation period is typically 3–6 days. The initial illness presents as a non-specific
febrile illness with sudden onset of fever, headache, myalgias, nausea, and vomit-
ing [2]. Most patients improve after the initial presentation; however, approximately
15% of patients progress, after a brief remission of hours to 1 day, to more severe
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disease with jaundice, hemorrhagic symptoms, and multisystem organ failure. The
case–fatality ratio for patients with hepatorenal dysfunction is 20–50% [2].
The preliminary diagnosis is based on the patient’s clinical features and
travel details. Laboratory diagnosis is typically made by detecting virus-specific
immunoglobulin M (IgM) antibodies, followed by confirmation by more specific
antibody testing, such as a plaque reduction neutralization test. Samples collected in
the first few days of the illness may be positive by YF virus isolation or nucleic acid
amplification tests.
No specific medications are available to treat YF virus infections; treatment is sup-
portive (e.g., rest, fluids, analgesics, and antipyretics).
Yellow fever among travelers
A traveler’s risk for acquiring YF is determined by various factors, including immu-
nization status, travel details, and local rate of virus transmission at the destination
during the time of travel [4]. Although reported cases of human disease are the prin-
cipal indicator of disease risk, case reports may be absent because of a low level of
transmission, a high level of immunity in the population (e.g., because of vacci-
nation), or insensitive surveillance. This “epidemiologic silence” does not equate to
absence of risk and should not lead to travel without protective measures.
From 1970 through 2012, nine YF cases were reported in unvaccinated travelers
from the United States and Europe and one in a vaccinated traveler [2]. Eight of the
nine unvaccinated travelers died and the vaccinated traveler survived.
For a 2-week stay, the estimated risks for illness and death attributable to YF for
an unvaccinated traveler visiting an endemic area of West Africa are 50 and 10 cases
per 100,000, respectively; for South America, the risks for illness and death are 5 and
1 case per 100,000, respectively [3].
Prevention
All travelers to YF-endemic countries should be advised of the disease risk and pre-
vention methods, including personal protective measures and vaccine.
Personal protection measures
All travelers should take precautions to avoid mosquito bites, including using insect
repellent, wearing permethrin-impregnated clothing, and staying in accommodations
with screened or air-conditioned rooms [5].
Vaccines
All YF vaccines currently manufactured are live-attenuated viral vaccines. YF vaccine
is recommended for people aged 9 months or more who are traveling to or living
in areas with risk for YF virus transmission in South America and Africa [6,7]. In
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addition, some countries require proof of YF vaccination for entry. To minimize the
risk of serious adverse events, clinicians should observe the contraindications to and
precautions for vaccination and vaccinate only persons who are at risk for exposure
or are visiting a country that requires proof of vaccination for entry [6].
Vaccine administration
For persons of all ages for whom vaccination is indicated, a single subcutaneous
injection of reconstituted vaccine should be administered. In 2013, the World Health
Organization (WHO) stated that a single dose of YF vaccine is sufficient to confer
life-long protective immunity against YF disease, and a booster dose is not neces-
sary [6]. However, the International Health Regulations (IHR) continue to require
revaccination at 10-year intervals. Therefore, clinicians and travelers should review
country entry requirements, including for booster doses, prior to traveling [7].
Vaccine safety and adverse reactions
Reactions to YF vaccine are generally mild; 10–30% of vaccinees report mild systemic
adverse events, including low-grade fever, headache, and myalgias [2].
Three well-characterized serious adverse events occur following YF vaccine
administration: immediate hypersensitivity or anaphylactic reactions, YF vaccine-
associated neurologic disease (YEL-AND), and YF vaccine-associated viscerotropic
disease (YEL-AVD) [4].
• Immediate hypersensitivity reactions are characterized by rash, urticaria, and/or
bronchospasm. Anaphylaxis after YF vaccine is reported to occur at a rate of 0.8–1.8
cases per 100,000 doses distributed.
• YEL-AND manifests as distinct clinical syndromes, including meningoencephalitis,
Guillain–Barré syndrome, and acute disseminated encephalomyelitis. Illness onset
is 3–28 days after vaccination, and almost all cases have been reported in first-time
vaccinees [4]. YEL-AND is rarely fatal. The incidence of YEL-AND among US trav-
elers is reported to be 0.4–0.8 per 100,000 doses distributed [4].
• YEL-AVD is similar to wild-type disease, with widespread vaccine virus dissemina-
tion, and often multisystem organ failure and death [4]. More than 60 cases have
been reported worldwide. Symptom onset is 0–8 days after vaccination, and all
cases have been reported in first-time vaccinees. The case–fatality ratio is 63% [2].
The incidence of YEL-AVD among US travelers is 0.3–0.4 cases per 100,000 doses
of vaccine distributed [4].
Contraindications
Persons who have a contraindication to YF vaccination should be not vaccinated and
should avoid travel to YF-endemic areas. If travel to endemic areas is unavoidable,
the clinician should provide a medical waiver and inform the traveler of increased
risk for YF associated with lack of vaccination, and also protective measures.
Infants younger than 6 months
YF vaccine is contraindicated for infants aged <6 months because of a relatively high
rate of YEL-AND documented in vaccinated young infants [2].
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Hypersensitivity
YF vaccine is contraindicated for people with a history of hypersensitivity to any of
the vaccine components, including eggs, egg products, chicken proteins, and gelatin.
Skin testing and desensitization can be performed (see the vaccine package insert) in
persons needing vaccination but for whom there is a concern about hypersensitivity
reaction to the vaccine.
Altered immune status
YF vaccine is contraindicated for people with altered immune status caused by any
of the following conditions [4,6]:
• Thymus disorder associated with abnormal immune cell function, such as thy-
moma or myasthenia gravis.
• AIDS or other clinical manifestations of HIV, including people with CD4T-
lymphocyte values <200/mm3 or <15% of total lymphocytes for children aged
<6 years.
• Primary immunodeficiencies, malignant neoplasms, and transplantation.
• People whose immunologic response is either suppressed or modulated by cur-
rent or recent radiation therapies or drugs. Drugs with known immunosuppres-
sive or immunomodulatory properties include, but are not limited to, high-dose
systemic corticosteroids, alkylating drugs, antimetabolites, tumor necrosis factor-𝛼
inhibitors, interleukin blocking agents, and other monoclonal antibodies targeting
immune cells [5]. If these therapies are discontinued, YF vaccine should be deferred
until immune function has improved.
Family members of people with altered immune status, who themselves have no
contraindications, can receive YF vaccine.
Precautions
If a person who has a condition that is considered a precaution to YF vaccination
cannot postpone or avoid travel to YF-endemic countries, vaccination can be consid-
ered based on weighing risk versus benefits. If international travel requirements, not
risk of YF, are the only reason for vaccination, the person should be excused from YF
immunization and issued a waiver.
Infants aged 6–8 months
Age 6–8 months is a precaution for YF vaccination. Two cases of YEL-AND have been
reported among infants aged 6–8 months [4].
Adults 60 years of age or older
Age 60 years or more is a precaution for YF vaccination because the reporting rate
for YEL-AND and YEL-AVD is increased among people aged 60 years or more [4].
Given that YEL-AND and YEL-AVD are seen almost exclusively in primary vacci-
nees, caution should be exercised with older travelers who are receiving their first YF
vaccination.
Asymptomatic HIV infection with moderate immune suppression
Asymptomatic HIV infection with CD4T-lymphocyte values 200–499/mm3 or
15–24% of total lymphocytes for children aged <6 years is associated with moderate
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immune suppression and hence is a precaution for YF vaccination. The relatively few
observational studies performed have reported no serious adverse events following
YF vaccination among patients considered moderately immunosuppressed based on
their CD4 counts.
Note. If an asymptomatic HIV-infected person has no evidence of immune sup-
pression based on CD4 counts (CD4T-lymphocyte values ≥500/mm3 or ≥25% of
total lymphocytes for children aged <6 years), YF vaccine can be administered if rec-
ommended.
Pregnancy
Pregnancy is a precaution for YF vaccine administration. The safety of YF vaccination
during pregnancy has not been studied in a large prospective trial. However, among
pregnant women who received YF vaccination, limited studies have found no major
malformations in their infants, and results are conflicting regarding an association
with spontaneous abortions. The seroconversion rate among women vaccinated dur-
ing pregnancy is variable andmight depend on the trimester of vaccination. Although
there are no specific data, women should be advised to wait 4 weeks after YF vacci-
nation before conceiving.
Breastfeeding
Breastfeeding is a precaution for YF vaccine administration. Three YEL-AND cases
have been reported in exclusively breastfed infants, aged <1 month, whose mothers
were vaccinated with YF vaccine [2].
Simultaneous administration of other vaccines
Because no evidence exists that inactivated vaccines interfere with the immune
response to YF vaccine, they can be administered either simultaneously or at any
time before or after YF vaccination. YF vaccine should be given simultaneously
or 30 days apart from other live-virus vaccines because the immune response
to one live-virus vaccine might be impaired if administered within 30 days of
another live-virus vaccine [6]. However, oral typhoid vaccine can be administered
simultaneously or at any interval before or after YF vaccine.
International certificate of vaccination or prophylaxis
(ICVP)
The IHR allow countries to require proof of YF vaccination from travelers, even if
only in transit, arriving from a country with risk of YF virus transmission, to prevent
importation and indigenous spread of YF virus [7]. Some countries require evidence
of vaccination from all entering travelers [5]. Travelers without proof of YF vacci-
nation who arrive in a country with a YF vaccination entry requirement may be
quarantined for up to 6 days, refused entry, or vaccinated on-site.
As proof of YF vaccination, all vaccinees should possess a completed International
Certificate of Vaccination or Prophylaxis (ICVP) validated with the provider’s signa-
ture and the YF vaccination stamp of the administering YF vaccination center [5].
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The ICVP must be signed by a medical provider supervising the administration of the
vaccine, who may be a licensed physician or a healthcare worker designated by the
physician.
An incomplete ICVP is not considered valid, and the traveler could be treated the
same as a person without proof of vaccination at the port of entry. The ICVP is valid
for 10 years, beginning 10 days after the date of vaccination. When a booster dose
of the vaccine is given within this 10-year period, the certificate is considered valid
from the date of revaccination.
Medical waivers (exemptions)
A traveler who has a specific contraindication to YF vaccine and who cannot avoid
travel to a country requiring vaccination should be issued a waiver before departure.
The clinician issuing a waiver should fill out and sign the Medical Contraindications
to Vaccination section of the ICVP and give the traveler a signed and dated exemption
letter on letterhead stationery. The letter should clearly state the contraindications to
vaccination and bear the stamp of the YF vaccination center. The clinician should
also inform the traveler of the increased risk for YF associated with lack of vaccina-
tion and how to minimize this risk by avoiding mosquito bites. Reasons other than
medical contraindications or precautions are not acceptable for exemption from vac-
cination. The traveler should be advised that issuance of a waiver does not guarantee
its acceptance by the destination country.
Requirements versus recommendations
Country entry requirements for proof of YF vaccination under the IHR differ from
YF vaccination recommendations, such as those published by the WHO [5,7]. YF
vaccine entry requirements are established by countries to prevent the importation
and transmission of YF virus. Travelers must comply with these to enter the country,
unless they have been issued a medical waiver. Country requirements are subject to
change at any time; therefore, travelers are encouraged to check with the relevant
embassy or consulate before departure.
YF vaccine recommendations are advice given by public health authorities to pre-
vent YF virus infections among travelers. Recommendations are subject to change
at any time because of changes in YF virus circulation, and travelers should check
relevant websites for updates.
YF risk classification for travelers
The four categories of risk for YF virus transmission apply to all geographic areas:
endemic, transitional, low potential for exposure, and no risk [1]. YF vaccination is
recommended for travel to endemic and transitional areas. Although vaccination is
generally not recommended for travel to areas with low potential for exposure, it
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Figure 8.1 Yellow fever vaccine recommendations. Source: Adapted from Centers for Disease
Control and Prevention 2014 [5].
might be considered for a small subset of travelers who may be at increased risk for
exposure to YF virus because of prolonged travel, heavy exposure to mosquitoes, or
inability to avoid mosquito bites.
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